Maurizio Montella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maurizio Montella has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Anna Crispo
Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy
10 shared publications Gabriella Fabbrocini
Department of Biology and Cellular and Molecular Pathology, Medical Statistical Division, Faculty of Medicine, Federico II University, Via Pansini, Naples, Italy
4 shared publicationsMario Tamburini
Department of Epidemiology, National Cancer Institute, G. Pascale Foundation, Via M. Semmola, 80131 Naples, Italy
4 shared publicationsDomenico Ronga
Transfusion Center, National Cancer Institute, “G. Pascale” Foundation and
3 shared publications- Francesco Izzo
Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via Mariano Semmola, 80131 Naples, Italy
3 shared publications - Gerardo Botti
Scientific Direction, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, 80131 Naples, Italy
3 shared publications
Latest Publications
- Open Access
- 29 November 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Tumor characteristics and prognosis in familial breast cancer
Approximately 5–10% of breast cancers are hereditary and their biology and prognosis appear to differ from those of sporadic breast cancers. In this study we compared the biological features and clinical characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic disease, and correlated these findings with clinical outcome. We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome (disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor [PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months. BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade, nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and 37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0% (p <0.0001) and the incidence of second primary tumors (non breast) was 9, 1 and 2% (p <0.0001) in BRCA-positive, BRCA-wild type and sporadic breast cancer, respectively. Median disease-free survival in years was 29 in BRCA-wild type, 19 in BRCA-positive and 14 in sporadic breast cancer patients (log-rank = 0.007). Median overall survival in years was not reached for BRCA-wild type, 19 for BRCA-positive and 13 for sporadic breast cancer patients (log-rank <0.0001). At multivariate analyses only BRCA-wild type status was related to a significant improvement in overall survival versus the sporadic breast cancer group (HR = 0,51; 95% CI (0,28–0,93) p = 0.028). The biology and outcome of breast cancer differ between patients with BRCA mutations, patients with a family history but no BRCA mutations and patients with sporadic breast cancer.
- 29 November 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Open AccessTumor characteristics and prognosis in familial breast cancer
Approximately 5–10% of breast cancers are hereditary and their biology and prognosis appear to differ from those of sporadic breast cancers. In this study we compared the biological features and clinical characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic disease, and correlated these findings with clinical outcome. We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome (disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor [PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months. BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade, nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and 37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0% (p <0.0001) and the incidence of second primary tumors (non breast) was 9, 1 and 2% (p <0.0001) in BRCA-positive, BRCA-wild type and sporadic breast cancer, respectively. Median disease-free survival in years was 29 in BRCA-wild type, 19 in BRCA-positive and 14 in sporadic breast cancer patients (log-rank = 0.007). Median overall survival in years was not reached for BRCA-wild type, 19 for BRCA-positive and 13 for sporadic breast cancer patients (log-rank <0.0001). At multivariate analyses only BRCA-wild type status was related to a significant improvement in overall survival versus the sporadic breast cancer group (HR = 0,51; 95% CI (0,28–0,93) p = 0.028). The biology and outcome of breast cancer differ between patients with BRCA mutations, patients with a family history but no BRCA mutations and patients with sporadic breast cancer.
- Open Access
- 1 December 2009
- Published by Elsevier in The Breast
- Vol. 18 (6) , 382-386
Association between mode of breast cancer detection and diagnosis delay
- 1 December 2009
- Published by Elsevier in The Breast
- Vol. 18 (6) , 382-386
Open AccessAssociation between mode of breast cancer detection and diagnosis delay
- 1 September 2002
- Published by Elsevier in Preventive Medicine
- Vol. 35 (3) , 271-277
An Assessment of Factors Related to Tumor Thickness and Delay in Diagnosis of Melanoma in Southern Italy
- 1 September 2002
- Published by Elsevier in Preventive Medicine
- Vol. 35 (3) , 271-277
An Assessment of Factors Related to Tumor Thickness and Delay in Diagnosis of Melanoma in Southern Italy
- 1 October 2001
- Published by Wiley in Liver International
- Vol. 21 (5) , 335-341
HCV and cancer: a case‐control study in a high‐endemic area
Background/Aims: HCV is a RNA virus that cannot be integrated with the host genome; it can, however, exert its oncogenic potential indirectly by contributing to the modulatory effects of the host immune system, probably through a capacity to elude the immune system. We have carried out a case‐controlled study on the different oncological pathologies which have, to date, been shown to have a relationship with HCV. Methods: We screened 495 patients with different types of cancer: 114 cases of liver cancer, 41 of multiple myeloma, 111 non‐Hodgkin’s lymphomas, 130 thyroid cancers, 63 cases of Hodgkin’s disease. The controls were 226 patients with no history of cancer. The relationship between each cancer and HCV infection was assessed by means of odds ratios (OR) and corresponding 95% confidence intervals. Results: Risks were greater for liver cancer (OR=32.9 95% CI 16.5–65.4, pp=0.0004) and B‐cell non‐Hodgkin’s lymphoma (OR=3.7 95% CI 1.9–7.4, p=0.0001). For Hodgkin’s disease there was no significant association (p=0.3). An association between HCV and thyroid cancer was noted (OR=2.8 95% CI 1.2–6.3, p=0.01). Conlusion: Our study is particularly important for public health since the high prevalence of HCV in the South of Italy gives reason to expect increases in not only liver cancer, but also tumors associated with the immune system and thyroid cancer in years to come.
- 1 October 2001
- Published by Wiley in Liver International
- Vol. 21 (5) , 335-341
HCV and cancer: a case‐control study in a high‐endemic area
Background/Aims: HCV is a RNA virus that cannot be integrated with the host genome; it can, however, exert its oncogenic potential indirectly by contributing to the modulatory effects of the host immune system, probably through a capacity to elude the immune system. We have carried out a case‐controlled study on the different oncological pathologies which have, to date, been shown to have a relationship with HCV. Methods: We screened 495 patients with different types of cancer: 114 cases of liver cancer, 41 of multiple myeloma, 111 non‐Hodgkin’s lymphomas, 130 thyroid cancers, 63 cases of Hodgkin’s disease. The controls were 226 patients with no history of cancer. The relationship between each cancer and HCV infection was assessed by means of odds ratios (OR) and corresponding 95% confidence intervals. Results: Risks were greater for liver cancer (OR=32.9 95% CI 16.5–65.4, pp=0.0004) and B‐cell non‐Hodgkin’s lymphoma (OR=3.7 95% CI 1.9–7.4, p=0.0001). For Hodgkin’s disease there was no significant association (p=0.3). An association between HCV and thyroid cancer was noted (OR=2.8 95% CI 1.2–6.3, p=0.01). Conlusion: Our study is particularly important for public health since the high prevalence of HCV in the South of Italy gives reason to expect increases in not only liver cancer, but also tumors associated with the immune system and thyroid cancer in years to come.
- 1 September 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (9) , 775-781
HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity
- 1 September 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (9) , 775-781
HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity
- 1 April 2001
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 66 (3) , 209-215
An Assessment of Delays in Obtaining Definitive Breast Cancer Treatment in Southern Italy
Female population is medically underserved in Southern Italy (in comparison with other Italian regions). In a recent systematic review of published studies, delays of 3–6 months between symptom onset...
- 1 April 2001
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 66 (3) , 209-215
An Assessment of Delays in Obtaining Definitive Breast Cancer Treatment in Southern Italy
Female population is medically underserved in Southern Italy (in comparison with other Italian regions). In a recent systematic review of published studies, delays of 3–6 months between symptom onset...
- 1 February 2001
- Published by Wolters Kluwer Health in European Journal Of Cancer Prevention
- Vol. 10 (1) , 53-59
Determinant factors for diagnostic delay in operable breast cancer patients
Randomized trials of mammographic screening have provided strong evidence that early diagnosis and treatment of breast cancer can reduce the specific mortality. Moreover, in a recent systematic review of published studies, delays of 3–6 months between symptom onset and treatment have been clearly found to be associated with lower survival rates for breast cancer patients. The aim of this study was to examine delays registered among breast cancer patients in southern Italy, in order to recognize their determining factors so as to provide women with a better opportunity for survival. The variables examined were age (5 school years); symptom status at first presentation (symptomatic or asymptomatic); date of first symptom presentation; date of first consultation with a health provider; the type of health provider consulted; tumour size and nodal status according to the pTNM system. Time intervals were categorized into: 3 months for patient and medical delay; 1–3 months, 3–6 months, >6 months for overall delay. Patient delay was associated with age and education: a higher risk was found for women of over 65 years age (odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.5) and with ≤5 years school attendance (OR 3.3, 95% CI 2.0–5.6). Medical delay was seen to be associated with the professional figure: significant differences were found between senologists (oncologists exclusively dedicated to breast cancer operation) and other specialists (OR 3.5, 95% CI 1.5–8.4). Young age and symptomatic presentation were found to be high risk factors. Concerning tumour size in overall delay, in cases where the tumour was >2 cm the OR was 2.4 (95% CI 1.5–3.7). Our study suggests that diagnostic delay can be reduced by providing more efficient training programmes for members of the medical profession and by producing educational training programmes targeted specifically at each age category (i.e. in older women more attention to education in prevention; in younger women correct information about mammography and specialized structures).
- 1 February 2001
- Published by Wolters Kluwer Health in European Journal Of Cancer Prevention
- Vol. 10 (1) , 53-59
Determinant factors for diagnostic delay in operable breast cancer patients
Randomized trials of mammographic screening have provided strong evidence that early diagnosis and treatment of breast cancer can reduce the specific mortality. Moreover, in a recent systematic review of published studies, delays of 3–6 months between symptom onset and treatment have been clearly found to be associated with lower survival rates for breast cancer patients. The aim of this study was to examine delays registered among breast cancer patients in southern Italy, in order to recognize their determining factors so as to provide women with a better opportunity for survival. The variables examined were age (5 school years); symptom status at first presentation (symptomatic or asymptomatic); date of first symptom presentation; date of first consultation with a health provider; the type of health provider consulted; tumour size and nodal status according to the pTNM system. Time intervals were categorized into: 3 months for patient and medical delay; 1–3 months, 3–6 months, >6 months for overall delay. Patient delay was associated with age and education: a higher risk was found for women of over 65 years age (odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.5) and with ≤5 years school attendance (OR 3.3, 95% CI 2.0–5.6). Medical delay was seen to be associated with the professional figure: significant differences were found between senologists (oncologists exclusively dedicated to breast cancer operation) and other specialists (OR 3.5, 95% CI 1.5–8.4). Young age and symptomatic presentation were found to be high risk factors. Concerning tumour size in overall delay, in cases where the tumour was >2 cm the OR was 2.4 (95% CI 1.5–3.7). Our study suggests that diagnostic delay can be reduced by providing more efficient training programmes for members of the medical profession and by producing educational training programmes targeted specifically at each age category (i.e. in older women more attention to education in prevention; in younger women correct information about mammography and specialized structures).
- 1 November 2000
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 6 (5)
HCV and hepatocellular carcinoma: A case-control study in an area of hyperendemicity.
HCV is an RNA virus that cannot be integrated with the host genome; it can, however, exert its oncogenetic potential indirectly by contributing to the modulator effects of the host immune system probably through a capacity to escape the immune system. We have carried out a case controlled study in a hyperendemic area on HCV infection and liver cancer. We screened 114 liver cancer and 226 controls. All patients were at first diagnosis and examined. For liver cancer the risk was (OR=32.9, 95% CI 16.5-65.4, p<0.0001). Our study is particularly important for public health since it shows that in the South of Italy, because of the high prevalence of HCV and the high life expectancy, there are good reasons to suppose that the incidence rate of liver cancer will continue to increase in the next few years.
- 1 November 2000
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 6 (5)
HCV and hepatocellular carcinoma: A case-control study in an area of hyperendemicity.
HCV is an RNA virus that cannot be integrated with the host genome; it can, however, exert its oncogenetic potential indirectly by contributing to the modulator effects of the host immune system probably through a capacity to escape the immune system. We have carried out a case controlled study in a hyperendemic area on HCV infection and liver cancer. We screened 114 liver cancer and 226 controls. All patients were at first diagnosis and examined. For liver cancer the risk was (OR=32.9, 95% CI 16.5-65.4, p<0.0001). Our study is particularly important for public health since it shows that in the South of Italy, because of the high prevalence of HCV and the high life expectancy, there are good reasons to suppose that the incidence rate of liver cancer will continue to increase in the next few years.
- Open Access
- 24 July 2000
- Published by Wiley in International Journal of Cancer
- Vol. 87 (4) , 611-612
Is hepatitis C virus infection associated with thyroid cancer? A case-control study
- 24 July 2000
- Published by Wiley in International Journal of Cancer
- Vol. 87 (4) , 611-612
Open AccessIs hepatitis C virus infection associated with thyroid cancer? A case-control study
- 29 February 2000
- Published by Elsevier in Preventive Medicine
- Vol. 30 (2) , 174-177
Changing Patterns of Breast Cancer Stage at Diagnosis in Southern Italy: Hospital Data as Indicators of Progressive Changes
- 29 February 2000
- Published by Elsevier in Preventive Medicine
- Vol. 30 (2) , 174-177
Changing Patterns of Breast Cancer Stage at Diagnosis in Southern Italy: Hospital Data as Indicators of Progressive Changes